Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
23 stopped studies mapped to Malignant Salivary Gland Neoplasm and descendants · 91% state a reason
Over the 23 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05286827 | Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma | Phase 2 | terminated | Mar 18, 2022 | National Cancer Institute (NCI) | The study was terminated due to low accrual and insufficient efficacy seen in first few… | Efficacy / futility |
| NCT04119453 | A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent… | Phase 2 | terminated | Oct 8, 2019 | Elevar Therapeutics | The RM-202 study was terminated by the Sponsor due to redirection of the rivoceranib development… | Other (stated, no rule matched) |
| NCT06322576 | 177Lu-PSMA (177Lu-PNT2002) in PSMA-Positive Adenoid Cystic Carcinoma | Phase 2 | terminated | Mar 21, 2024 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Sponsor is no longer producing the study drug, so it was not possible to complete the study. | Other (stated, no rule matched) |
| NCT05194072 | A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors | Phase 1 | terminated | Jan 18, 2022 | Seagen, a wholly owned subsidiary of Pfizer | The trial was terminated for strategic reasons. The decision was not based on any safety and/or… | Safety / toxicity |
| NCT04249947 | P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant… | Phase 1 | terminated | Jan 31, 2020 | Poseida Therapeutics, Inc. | Study closed | Other (stated, no rule matched) |
| NCT06199453 | The Evaluation of the Effectiveness, Safety and Tolerability of Treatment, Using a…(LuRM_ACC/2023) | Phase 2 | withdrawn | Jan 10, 2024 | Maria Sklodowska-Curie National Research Institute of Oncology | Administrative reasons | Other (stated, no rule matched) |
| NCT03422679 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and… | Phase 1 / Phase 2 | terminated | Feb 6, 2018 | Cellestia Biotech AG | business reason | Sponsor / business decision |
| NCT01332279 | Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With… | Phase 1 | withdrawn | Apr 11, 2011 | Fox Chase Cancer Center | Pharmaceutical co. withdrew support. Study was never activated and did not accrue any patients. | Enrollment / accrual |
| NCT04832438 | 9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma | Phase 2 | withdrawn | Apr 5, 2021 | Actuate Therapeutics Inc. | Replaced by NCT05010629 | Other (stated, no rule matched) |
| NCT03729297 | Cabozantinib in Advanced Salivary Gland Cancer Patients(Cabo ASAP) | Phase 2 | terminated | Nov 2, 2018 | Radboud University Medical Center | safety issues | Safety / toxicity |
| NCT01249443 | Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors… | Phase 1 | terminated | Nov 29, 2010 | AIDS Malignancy Consortium | Inadequate accrual rate | Enrollment / accrual |
| NCT00416793 | Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer | Phase 2 | terminated | Dec 28, 2006 | National Cancer Institute (NCI) | Study was terminated due to poor accrual | Enrollment / accrual |
| NCT01739439 | Chemoradiation and Radiosurgery Boost in Treating Patients With Locally Advance… | Phase 1 | terminated | Dec 3, 2012 | Fox Chase Cancer Center | Slow accrual | Enrollment / accrual |
| NCT01164566 | Esophagoscopy in Evaluating Treatment in Patients With Stage I-IV Head and Neck Cancer… | N/A | terminated | Jul 16, 2010 | Wake Forest University Health Sciences | Inadequate Recruitment | Enrollment / accrual |
| NCT01283178 | Phase I Study of IMRT and Molecular-Image Guided Adaptive Radiation Therapy for Advanced… | Phase 1 | terminated | Jan 25, 2011 | Virginia Commonwealth University | The study was terminated. The data analysis was futile with only 3 accruals. PI opted to terminate… | Enrollment / accrual |
| NCT01528137 | Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer… | Phase 1 | terminated | Feb 7, 2012 | Stanford University | Negative data from another trial led to termination of this trial by sponsor. | Other (stated, no rule matched) |
| NCT00984217 | Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies | Phase 2 | withdrawn | Sep 25, 2009 | University of Pittsburgh | Decided not to pursue at UPCI | Other (stated, no rule matched) |
| NCT02042885 | A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With… | Phase 1 / Phase 2 | terminated | Jan 23, 2014 | Otsuka Novel Products GmbH | not stated | Not stated |
| NCT01254734 | Transoral Robotic Surgery in Treating Patients With Benign or Stage I-IV Head and Neck… | N/A | terminated | Dec 7, 2010 | City of Hope Medical Center | The study will be rewritten as a data registry study | Other (stated, no rule matched) |
| NCT01741597 | Dynamic Contrast Enhanced MRI in Patients With Advanced Breast or Pancreatic Cancer With… | Phase 1 | withdrawn | Dec 5, 2012 | City of Hope Medical Center | PI chose to close the study | Other (stated, no rule matched) |
| NCT00906360 | Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or… | Phase 1 | terminated | May 21, 2009 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00126607 | Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer | Phase 2 | terminated | Aug 4, 2005 | National Cancer Institute (NCI) | Poor accrual. | Enrollment / accrual |
| NCT00081211 | Intratumoral PV701 in Treating Patients With Advanced or Recurrent Unresectable Squamous… | Phase 1 | terminated | Apr 8, 2004 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Aug 14, 2026source: clinicaltrials